BioPharma Dive January 17, 2019
Bristol-Myers Squibb’s splashy $74 billion Celgene buy is set to reset the top ranks of pharma, but the industry’s year ahead will be shaped more directly by larger trends impacting the sector’s perception, investment and future growth.
Public criticism and scrutiny from lawmakers will likely remain, keeping biotech and pharma under pressure. At the same time, a cooperative FDA and scientific advances in oncology, cell and gene therapy should continue to serve as a tailwind, generating new approvals and investor optimism.
Digital opportunities, including in artificial intelligence, have also proved attractive to drugmakers, spurring changes among executive teams.
Here are seven trends to watch as 2019 unfolds:
Among Elijah Cummings’ first acts as chairman...
Today's Sponsors
Today's Sponsor